A larger sample size is needed to further investigate whether CDKN2A/B deletion is associated with BCR-ABL1 positivity combined with IKZF1 deletion and how the coexistence of the three affects the prognosis of pediatric ALL patients. The gene discussed is CDKN2A; the disease is acute lymphoblastic leukemia.